Prothena Corp PLC (NAS:PRTA)
$ 16.21 0.33 (2.08%) Market Cap: 872.24 Mil Enterprise Value: 364.47 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 70/100

Prothena Corporation PLC at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 09:15PM GMT
Release Date Price: $28 (-5.56%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Great. Good afternoon, everybody. Thanks for joining us here for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Really pleased to have Prothena with us and the team from Prothena.

Quickly before we get started, I just need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosure.

So happy to have Gene Kinney, who's the CEO; and Wagner Zago, who's the CSO.

Questions & Answers

Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

I guess I thought a good place to start. So you guys are obviously focused across both in AD or, I guess, I'd say neuroscience and amyloid science or amyloid pipeline. So maybe just give a little bit of background on the company and sort of the core underlying technology and how you got

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot